188 related articles for article (PubMed ID: 33662459)
21. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid
Yang DM; Palma D; Louie A; Malthaner R; Fortin D; Rodrigues G; Yaremko B; Laba J; Gaede S; Warner A; Inculet R; Lee TY
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):94-101. PubMed ID: 30281918
[TBL] [Abstract][Full Text] [Related]
22. Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients.
Qin Q; Shi A; Zhang R; Wen Q; Niu T; Chen J; Qiu Q; Wan Y; Sun X; Xing L
Thorac Cancer; 2020 Apr; 11(4):964-972. PubMed ID: 32061061
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
Takeda K; Takanami K; Shirata Y; Yamamoto T; Takahashi N; Ito K; Takase K; Jingu K
J Radiat Res; 2017 Nov; 58(6):862-869. PubMed ID: 29036692
[TBL] [Abstract][Full Text] [Related]
24. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
[TBL] [Abstract][Full Text] [Related]
25. Machine learning based on clinico-biological features integrated
Ren C; Zhang J; Qi M; Zhang J; Zhang Y; Song S; Sun Y; Cheng J
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1538-1549. PubMed ID: 33057772
[TBL] [Abstract][Full Text] [Related]
26. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
[TBL] [Abstract][Full Text] [Related]
27. Use of radiomics based on
Zhou Y; Ma XL; Zhang T; Wang J; Zhang T; Tian R
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2904-2913. PubMed ID: 33547553
[TBL] [Abstract][Full Text] [Related]
28. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
[TBL] [Abstract][Full Text] [Related]
29. CT radiomics analysis of lung cancers: Differentiation of squamous cell carcinoma from adenocarcinoma, a correlative study with FDG uptake.
Tomori Y; Yamashiro T; Tomita H; Tsubakimoto M; Ishigami K; Atsumi E; Murayama S
Eur J Radiol; 2020 Jul; 128():109032. PubMed ID: 32361604
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
[TBL] [Abstract][Full Text] [Related]
31. Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis.
Wu J; Aguilera T; Shultz D; Gudur M; Rubin DL; Loo BW; Diehn M; Li R
Radiology; 2016 Oct; 281(1):270-8. PubMed ID: 27046074
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer.
Carlsson A; Nair VS; Luttgen MS; Keu KV; Horng G; Vasanawala M; Kolatkar A; Jamali M; Iagaru AH; Kuschner W; Loo BW; Shrager JB; Bethel K; Hoh CK; Bazhenova L; Nieva J; Kuhn P; Gambhir SS
J Thorac Oncol; 2014 Aug; 9(8):1111-9. PubMed ID: 25157764
[TBL] [Abstract][Full Text] [Related]
33. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
[TBL] [Abstract][Full Text] [Related]
34. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Pastis NJ; Greer TJ; Tanner NT; Wahlquist AE; Gordon LL; Sharma AK; Koch NC; Silvestri GA
Chest; 2014 Aug; 146(2):406-411. PubMed ID: 24577678
[TBL] [Abstract][Full Text] [Related]
35.
Liu F; Xiang Z; Li Q; Fang X; Zhou J; Yang X; Lin H; Yang Q
Clin Radiol; 2024 Jan; 79(1):e147-e155. PubMed ID: 37884401
[TBL] [Abstract][Full Text] [Related]
36. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860
[TBL] [Abstract][Full Text] [Related]
37. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [
Yang DM; Palma DA; Kwan K; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko BP; Laba J; Gaede S; Warner A; Inculet R; Lee TY
Radiat Oncol; 2021 Jan; 16(1):11. PubMed ID: 33441162
[TBL] [Abstract][Full Text] [Related]
38. Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRT.
Huynh E; Coroller TP; Narayan V; Agrawal V; Romano J; Franco I; Parmar C; Hou Y; Mak RH; Aerts HJ
PLoS One; 2017; 12(1):e0169172. PubMed ID: 28046060
[TBL] [Abstract][Full Text] [Related]
39. 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.
Carvalho S; Leijenaar RTH; Troost EGC; van Timmeren JE; Oberije C; van Elmpt W; de Geus-Oei LF; Bussink J; Lambin P
PLoS One; 2018; 13(3):e0192859. PubMed ID: 29494598
[TBL] [Abstract][Full Text] [Related]
40. Value of pre-therapy
Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]